Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares (NGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.13 (market cap $6.57B), while National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares trades at $79.17 (market cap $78.25B). The key difference: National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares is far larger — about 11.9× Iovance Biotherapeutics Inc. Common Stock's market cap, and National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares pays a 4.14% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| IOVA | NGG | |
|---|---|---|
Market Cap | $6.57B | $78.25B |
Volume | 11,838,721 | 1,070,031 |
Sector | Health | Utilities |
52-Week High | $14.82 | $93.93 |
52-Week Low | $1.81 | $73.54 |
Typical Hold Time | 1 Days | — |
Enterprise Value | $6.50B | $136.28B |
Dividend Yield | — | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iovance Biotherapeutics (IOVA) trades at $14.50, down 0.41% on the day, with a bullish technical signal from moving averages. The company shows strong revenue growth, with 2026 guidance raised to $410–420 million, but remains unprofitable with a net income margin of -89.09%. Recent news highlights institutional buying and positive analyst sentiment driven by accelerating adoption of its Amtagvi therapy.
The outlook is optimistic due to expanding TIL therapy applications and raised revenue guidance, but high cash burn and lack of profitability pose significant risks. Analyst consensus is strongly bullish with a $13.44 price target, though the stock faces volatility from clinical trial outcomes and competitive pressures.
National Grid (NGG) trades at $78.23, up 1.44% on the day, with a market cap of approximately $48.3 billion. The stock shows stable technicals near its consensus price target of $79.25. Fundamentally, it maintains strong profitability with an 18.32% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights institutional buying and a focus on grid innovation, including AI adoption.
Outlook is cautiously positive with upside to the high target of $85.50, supported by earnings momentum and strategic investments. Risks include high debt levels and regulatory pressures. Analyst consensus leans buy (55%), but hold ratings reflect concerns over capital intensity and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares
National Grid plc is a British utility company that owns and operates electricity and gas transmission networks in Great Britain, and through its US Regulated business, operates electricity and gas transmission and distribution networks serving customers in New York and Massachusetts. Its shares trade on the NYSE as American Depositary Shares under the ticker NGG.
Read more on NGG →
